Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 6/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3223115 | 0.76 | CTSD (0.46) | CTSDFDPSF2ADRA2BKCNH2 | |
| SCHEMBL714498 | 0.76 | CTSD (0.46) | CTSDFDPSF2ADRA2BKCNH2 | |
| SCHEMBL1282816 | 0.76 | CTSD (0.46) | CTSDFDPSF2ADRA2BKCNH2 | |
| SCHEMBL1678422 | 0.76 | ADRA2B (0.49) | CTSDFDPSF2ADRA2BKCNH2 | |
| SCHEMBL14985489 | 0.76 | CTSD (0.46) | CTSDFDPSF2ADRA2BKCNH2 | |
| SCHEMBL7054279 | 0.76 | LIMK1 (0.51) | CTSDFDPSF2ADRA2BKCNH2 | |
| SCHEMBL5495415 | 0.76 | CTSD (0.46) | CTSDFDPSF2ADRA2BKCNH2 | |
| SCHEMBL6138610 | 0.75 | ALDH1A1 (0.64) | CTSDMAPTALDH1A1 | |
| SCHEMBL27316413 | 0.74 | RAB9A (0.50) | MEN1KMT2A | |
| SCHEMBL1950296 | 0.73 | MAPT (0.42) | MAPTALDH1A1MEN1KMT2ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450299-B2 | Substituted quinazoline derivatives as DNA methyltransferase inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-10-22 | — | — | US | disclosed |
| US-20180118717-A1 | Substituted Quinazoline Derivatives as DNA Methyltransferase Inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2018-05-03 | — | — | US | disclosed |
| US-20180118717-A1 | Substituted Quinazoline Derivatives as DNA Methyltransferase Inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2018-05-03 | — | — | US | disclosed |
| US-9951044-B2 | Quinazoline derivatives and their use as DNA methyltransferase inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2018-04-24 | — | — | US | disclosed |
| US-9951044-B2 | Quinazoline derivatives and their use as DNA methyltransferase inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2018-04-24 | — | — | US | disclosed |
| EP-3046917-B1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS | PF MEDICAMENT (FR) | 2017-11-08 | — | — | EP | disclosed |
| US-20160229834-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2016-08-11 | — | — | US | disclosed |
| US-20160229834-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2016-08-11 | — | — | US | disclosed |
| WO-2015040169-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2015-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450299-B2 | Substituted quinazoline derivatives as DNA methyltransferase inhibitors | DNMT1, DNMT3A, DNMT3B | CTSD 3919/4885FDPS 1565/4885F2 4716/4885 |
| US-20160229834-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS DNA METHYLTRANSFERASE INHIBITORS | DNMT1, DNMT3A, TPMT | CTSD 3995/4885FDPS 1656/4885F2 4712/4885 |
| US-20180118717-A1 | Substituted Quinazoline Derivatives as DNA Methyltransferase Inhibitors | DNMT1, DNMT3A, DNMT3B | CTSD 3919/4885FDPS 1565/4885F2 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.